Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD1QOH)

Drug Name
GNF-PF-2812 Drug Info
Synonyms
3-(4-Methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one; GNF-PF-2812; NSC663884; CHEMBL125044; 147508-58-5; 3-(4-methoxyphenyl)indeno[1,2-c]pyridazin-5-one; 5H-indeno[1,2-c]pyridazin-5-one, 3-(4-methoxyphenyl)-; AC1Q6KMT; AC1L8E6Y; Oprea1_523550; CBDivE_007579; MLS000691948; cid_379338; CTK7A3357; BDBM21618; KS-00001QSJ; MolPort-002-851-046; HMS2631I03; ZINC196663; STK336082; MMV666026; Indeno[1,2-c]pyridazin-5-one, 6; AKOS005075095; MCULE-6151549558; NSC-663884; SMR000333991; NCI60_021917
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
379338
TTD Drug ID
DMD1QOH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Angiotensin II receptor type-1 (AGTR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [2]
Olmesartan medoxomil DMWBHRY High blood pressure BA00 Approved [3]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [2]
Valsartan DMREUQ6 Chronic heart failure BD1Z Approved [2]
Candesartan DMRK8OT Chronic heart failure BD1Z Approved [4]
Telmisartan DMS3GX2 Hypertension BA00-BA04 Approved [5]
ANGIOTENSIN II DMLWQ27 Increase blood pressure BA04 Approved [6]
SARALASIN DMKS1DV Hypertension BA00-BA04 Approved [7]
Tasosartan DMM13DI Hypertension BA00-BA04 Approved [8]
Eprosartan DM07K2I Hypertension BA00-BA04 Approved [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin II receptor type-1 (AGTR1) TT8DBY3 AGTR1_HUMAN Inhibitor [1]

References

1 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
2 Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
3 Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
4 Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
5 Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
6 The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
7 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
8 Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
9 Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.